Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18972339 | 1.00 | L3MBTL1 (0.52) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL11990467 | 0.99 | L3MBTL1 (0.50) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL25542920 | 0.97 | CASP2 (0.50) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL4813304 | 0.95 | FAAH (0.49) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL6048384 | 0.95 | FAAH (0.49) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL19647019 | 0.95 | SMN1; SMN2 (0.48) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL6048378 | 0.95 | FAAH (0.49) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL6048382 | 0.95 | FAAH (0.49) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL19543157 | 0.95 | L3MBTL1 (0.45) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 | |
| SCHEMBL19703873 | 0.92 | CASP2 (0.49) | L3MBTL1CASP2NAAAFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691997-B2 | Macrocycles | LUMIPHORE, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3129350-B1 | MACROCYCLES | LUMIPHORE INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170183365-A1 | MACROCYCLES | LUMIPHORE, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-2470513-B1 | MACROCYCLIC HOPO CHELATORS | LUMIPHORE INC (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013187971-A2 | MACROCYCLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-19 | — | — | WO | disclosed |
| EP-2423201-A1 | Luminescent macrocyclic lanthanide complexes | The Regents of The University of California (US) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | L3MBTL1 551/4885CASP2 3804/4885NAAA 4693/4885 |
| US-11691997-B2 | Macrocycles | HCCS, ABCB7, AURKAIP1 | L3MBTL1 3201/4885CASP2 1636/4885NAAA 4586/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | L3MBTL1 551/4885CASP2 3804/4885NAAA 4693/4885 |
| US-20170183365-A1 | MACROCYCLES | HCCS, ABCB7, AURKAIP1 | L3MBTL1 3201/4885CASP2 1636/4885NAAA 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.